Inventor · disambiguated record
Gary E. Schiltz
Also filed as: SCHILTZ GARY · SCHILTZ GARY E
24 granted patents·14 pending applications·39 citations·filing 2008–2024
92Inventor score
Top patents by PatentIndex Score
38 records- 0187US9981968B2Substituted pyrrolo[2,3-d]pyrimidines for the treatment of cancer and proliferative disordersUNIV NORTHWESTERN·Filed 2015·Granted May 29, 2018·14 cites·18 claims
- 0284US10640502B2Therapeutic targeting of interleukin-1 receptor-associated kinase 4 (IRAK4) in cancers characterized by rearrangements in the mixed lineage leukemia gene (MLL-r)UNIV NORTHWESTERN·Filed 2018·Granted May 5, 2020·3 cites·19 claims
- 0383US10435375B2CXCR4 chemokine receptor modulatorsUNIV NORTHWESTERN·Filed 2016·Granted Oct 8, 2019·4 cites·8 claims
- 0481US9669014B2Small molecule inhibitors of superoxide dismutase expressionUNIV NORTHWESTERN·Filed 2016·Granted Jun 6, 2017·3 cites·8 claims
- 0580US10093668B2Substituted aromatic N-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (Mnk1) and 2 (Mnk2)UNIV NORTHWESTERN·Filed 2016·Granted Oct 9, 2018·5 cites·13 claims
- 0679US12492209B2Substituted [1,2,4]triazolo[4,3-c]pyrimidines that induce degradation of embryonic ectoderm development (EED) proteinUNIV NORTHWESTERN·Filed 2024·Granted Dec 9, 2025·0 cites·6 claims
- 0779US12491252B2Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2UNIV NORTHWESTERN·Filed 2024·Granted Dec 9, 2025·0 cites·12 claims
- 0879US11225483B2Substituted fused pyrrolo-diazepinones and uses thereofUNIV NORTHWESTERN·Filed 2019·Granted Jan 18, 2022·1 cites·14 claims
- 0979US8791267B2Biaryl PDE4 inhibitors for treating inflammatory, cardiovascular and CNS disordersSINGH JASBIR·Filed 2012·Granted Jul 29, 2014·4 cites·22 claims
- 1074US10851082B2Substituted aromatic n-heterocyclic compounds as inhibitors of mitogen-activated protein kinase interacting kinase 1 (MNK1) and 2 (MNK2)UNIV NORTHWESTERN·Filed 2018·Granted Dec 1, 2020·2 cites·14 claims
- 1173US2024376050A1Substituted pyrrolidones and piperidones as small molecule inhibitors of ezh2 and eed protein bindingUNIV NORTHWESTERN·Filed 2024·Application pending·0 cites
- 1272US12042543B2Substituted 3-amino-5-phenylbenzamide compounds as covalent inhibitors of enhancer zeste homolog 2 (EZH2) and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of EZH2UNIV NORTHWESTERN·Filed 2022·Granted Jul 23, 2024·0 cites·13 claims
- 1371US12311029B2Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) proteinUNIV NORTHWESTERN·Filed 2023·Granted May 27, 2025·0 cites·17 claims
- 1471US9688637B23-amidobenzamides and uses thereof for increasing cellular levels of A3G and other A3 family membersUNIV NORTHWESTERN·Filed 2015·Granted Jun 27, 2017·3 cites·13 claims
- 1571US2024207413A1Proteolysis-targeting chimeric molecules (protacs) that induce degradation of c-myc proteinUNIV NORTHWESTERN·Filed 2023·Application pending·0 cites
- 1669US11981678B2Substituted [1,2,4]triazolo[4,3-c]pyrimidin-5-amines and proteolysis-targeting chimeric derivatives thereof (PROTACs) that induce degradation of embryonic ectoderm development (EED) proteinUNIV NORTHWESTERN·Filed 2022·Granted May 14, 2024·0 cites·4 claims
- 1769US11919855B2Substituted pyrrolidones and piperidones as small molecule inhibitors of EZH2 and EED protein bindingUNIV NORTHWESTERN·Filed 2022·Granted Mar 5, 2024·0 cites·19 claims
- 1869US2025084040A1SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTSUNIV NORTHWESTERN·Filed 2024·Application pending·0 cites
- 1968US12252492B2Substituted fused pyrrolo-diazepinones and uses thereofUNIV NORTHWESTERN·Filed 2022·Granted Mar 18, 2025·0 cites·12 claims
- 2066US2024109903A1Substituted heterocycles for treating cancerUNIV NORTHWESTERN·Filed 2023·Application pending·0 cites
- 2164US11890346B2Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of c-MYC proteinUNIV NORTHWESTERN·Filed 2020·Granted Feb 6, 2024·0 cites·4 claims
- 2264US2009324569A1Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disordersDECODE GENETICS EHF·Filed 2008·Application pending·0 cites
- 2363US2024238304A1Small Molecule Degraders of DOT1L and Uses ThereofUNIV NORTHWESTERN·Filed 2023·Application pending·0 cites
- 2463US2024287033A1Degraders of tissue transglutaminase 2 (tg2)UNIV NORTHWESTERN·Filed 2024·Application pending·0 cites
- 2561US11839659B2Proteolysis-targeting chimeric molecules (PROTACs) that induce degradation of indoleamine 2,3-dioxygenase (IDO) proteinUNIV NORTHWESTERN·Filed 2021·Granted Dec 12, 2023·0 cites·10 claims
- 2661US2014301999A1Biaryl pde4 inhibitors for treating inflammatory, cardiovascular and cns disordersDECODE GENETICS EHF·Filed 2014·Application pending·0 cites
- 2761US2020039941A1Cxcr4 chemokine receptor modulatorsUNIV NORTHWESTERN·Filed 2019·Application pending·0 cites
- 2855US11453640B2Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapyUNIV NORTHWESTERN·Filed 2019·Granted Sep 27, 2022·0 cites·5 claims
- 2954US2023391714A1Inhibitors of the interaction between trip8b and hcn channels and uses thereof for treating neurological diseases and disordersUNIV NORTHWESTERN·Filed 2023·Application pending·0 cites
- 3051US12414995B2Bifunctional compounds comprising Apcin-A and their use in the treatment of cancerUNIV NORTHWESTERN·Filed 2020·Granted Sep 16, 2025·0 cites·17 claims
- 3149US11420957B2Substituted heterocycles as c-MYC targeting agentsUNIV NORTHWESTERN·Filed 2020·Granted Aug 23, 2022·0 cites·10 claims
- 3249US11370770B23-arylindazoles as selective MEK4 inhibitorsUNIV NORTHWESTERN·Filed 2020·Granted Jun 28, 2022·0 cites·25 claims
- 3347US12152007B2Substituted heterocycles as c-MYC targeting agentsUNIV NORTHWESTERN·Filed 2018·Granted Nov 26, 2024·0 cites·19 claims
- 3446US2021276960A1Inhibitors of tissue transglutaminase 2 (tg2) and uses thereofUNIV NORTHWESTERN·Filed 2021·Application pending·0 cites
- 3542US11142504B2Substituted heterocycles as c-MYC targeting agentsUNIV NORTHWESTERN·Filed 2018·Granted Oct 12, 2021·0 cites·13 claims
- 3641US2023041761A1Small molecule modulators of sigma-1 and sigma-2 receptors and uses thereofUNIV NORTHWESTERN·Filed 2019·Application pending·0 cites
- 3739US2019321345A1GLUT4 Selective Inhibitors for Cancer TherapyUNIV EMORY·Filed 2017·Application pending·0 cites
- 3834US2017253581A1SUBSTITUTED HETEROCYCLES AS c-MYC TARGETING AGENTSUNIV NORTHWESTERN·Filed 2017·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Gary E. Schiltz files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →